Reata Pharmaceuticals, Inc.
RETA · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $22,746 | $195 | $914 | $540 |
| % Growth | 11,564.6% | -78.7% | 69.3% | – |
| Cost of Goods Sold | $846 | $0 | $0 | $0 |
| Gross Profit | $21,900 | $195 | $914 | $540 |
| % Margin | 96.3% | 100% | 100% | 100% |
| R&D Expenses | $57,120 | $55,477 | $47,223 | $43,485 |
| G&A Expenses | $0 | $54,885 | $32,023 | $27,270 |
| SG&A Expenses | $45,690 | $54,885 | $32,023 | $27,270 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$104 | $288 | $277 | $272 |
| Operating Expenses | $103,103 | $110,650 | $79,523 | $71,027 |
| Operating Income | $192,998 | -$110,455 | -$71,469 | -$70,549 |
| % Margin | 848.5% | -56,643.6% | -7,819.4% | -13,064.6% |
| Other Income/Exp. Net | $274,201 | $0 | -$6,948 | -$8,453 |
| Pre-Tax Income | $192,998 | -$116,117 | -$85,557 | -$79,002 |
| Tax Expense | $0 | -$5,355 | -$55 | -$2,211 |
| Net Income | $192,998 | -$110,762 | -$85,502 | -$76,791 |
| % Margin | 848.5% | -56,801% | -9,354.7% | -14,220.6% |
| EPS | 5.12 | -3 | -2.35 | -2.1 |
| % Growth | 270.7% | -27.7% | -11.9% | – |
| EPS Diluted | 4.65 | -3 | -2.35 | -2.1 |
| Weighted Avg Shares Out | 41,507 | 36,948 | 36,321 | 36,537 |
| Weighted Avg Shares Out Dil | 41,507 | 36,948 | 36,321 | 36,537 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $7,973 | $11,017 | $10,959 | $10,664 |
| Depreciation & Amortization | $293 | $288 | $277 | $272 |
| EBITDA | $193,291 | -$110,167 | -$117,222 | -$68,066 |
| % Margin | 849.8% | -56,495.9% | -12,825.2% | -12,604.8% |